Discovers novel therapeutics based on ribonucleic acid interference (RNAi). Develops RNAi therapeutics for genetic medicines. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 45% a year over the last 4 years. Red columns mark years that ended in a loss.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 49% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 45% a year on average.
There is $2.9B in the vault; even if every debt were paid off, $1.6B would remain.
The company’s market value is 106 times its annual profit. Even a small disappointment could hit the price hard.
Over the last 12 months, executives reported 440 sells against just 80 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, ALNY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ALNY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (39/100) says the stock isn’t cheap.